Clostridium difficile infection: Update on diagnosis, epidemiology, and treatment strategies

Surgical Infections

Volumn 15, Issue 5, 2014, Pages 490-502

  To, Kathleen B ^a   Napolitano, Lena M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NITAZOXANIDE; RIFAMPICIN; RIFAXIMIN; TIGECYCLINE; TOLEVAMER; ANTIINFECTIVE AGENT;

ACTIVE IMMUNIZATION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONSULTATION; DISEASE CLASSIFICATION; FECAL TRANSPLANTATION; HUMAN; ILEOSTOMY; INFECTION CONTROL; LABORATORY TEST; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; TOTAL COLON RESECTION; TRANSPLANTATION; CLOSTRIDIUM INFECTIONS; ISOLATION AND PURIFICATION; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS;

EID: 84912046394     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2013.186     Document Type: Review

References (85)

1. Hall IC, O'Toole E. Intestinal flora in new-born infants: With a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935;49:390-402.
2. Bartlett JG. Clostridium difficile: History of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994;18 Suppl 4:S265-S272.
3. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMHJ 2014;171:51-58.
4. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gas-troenterol Clin North Am. 2001;30:753-777.
5. McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28: 140-145.
6. McDonald LC, Owings M, Jernigan JB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996 to 2003. Emerg Infect Dis 2006;12:409-415.
7. Harbrecht BG, Franklin GA, Shirley RM, et al. Statewide experience with Clostridium difficile colitis in academic and non-academic medical centers. Surg Infect (Larchmt) 2012;13:88-92.
8. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010;4:409-416.
9. Kelly CP, LaMont JT. Clostridium difficile-More difficult than ever. N Engl J Med 2008;359:1932-1940.
10. United Kingdom national statistics. Newport, United Kingdom: Office for National Statistics, UK Statistics Authority. www.statistics.gov.uk (Last accessed July 27, 2013).
11. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 2004; 171:466-472.
12. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449.
13. Micek ST, Schramm G, Morrow L, et al. Clostridium difficile infection: A multicenter study of epidemiology and outcomes in mechanically ventilated patients. Crit Care Med 2013;41:1968-1975.
14. Kelly CP. C. difficile infection: Tools for treatment and prevention. www.medscape.org/viewarticle/584850
15. Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clos-tridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-455.
16. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-1084.
17. Bartlett JG. Narrative review: The new epidemic of Clos-tridium difficile-associated enteric disease. Ann Intern Med 2006;145:758-64.
18. He M, Miyajima F, Roberts P, Ellison L, et al. Emergence and global spread of epidemic healthcare-associated Clos-tridium difficile. Nat Genet 2013;45:109-113.
19. Zerey M, Paton BL, Lincourt AE, et al. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt) 2007;8:557-566.
20. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-1034.
21. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-210.
22. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-2995.
23. Carroll KC. Tests for the diagnosis of Clostridium difficile infection: The next generation. Anaerobe 2011;17:170-174.
24. Quinn CD, Sefers SE, Babiker W, et al. C. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens. J Clin Microbiol 2010;48:603-605.
25. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterology 2013;108:478-498.
26. http://www.gastrointestinalatlas.com/English/Colon-and-Rectum/-Pseudomembranous-Colitis/-pseudomembranous- colitis/html
27. http://emedicine.medscape.com/), 2014
28. Available at: http://emedicine.medscape.com/article/366987-overview
29. Ash L, Baker ME, O'Malley CM Jr, et al. Colonic abnormalities on CT in adult hospitalized patients with Clos-tridium difficile colitis: Prevalence and significance of findings. AJR Am J Roentgenol 2006;186:1393-1400.
30. Macari M, Balthazar EJ, Megibow AJ. The accordion sign at CT: A nonspecific finding in patients with colonic edema. Radiology 1999;211:743-746.
31. Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy? AJR Am J Roentgenol 2001;176:635-639.
32. Joseph J, Singhal S, Patel GM, Anand S. Clostridium difficile colitis: Review of the therapeutic approach. Am J Ther 2014;21:385-394.
33. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-307.
34. Aslam S, Hamill RJ, Musher DM. Treatment of Clos-tridium difficile-associated disease: Old therapies and new strategies Lancet Infect Dis 2005;5:549-557.
35. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: Response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995;36:673-679.
36. Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect 2011;12:235-239.
37. Shah D, Dang MD, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010;8:555-564.
38. Venuto C, Butler M, Ashley ED, Brown J. Alternative therapies for Clostridium difficile infections. Review of therapeutics. Pharmacotherapy 2010;30:1266-1278.
39. Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364: 422-431.
40. DuPont HL. The search for effective treatment of Clos-tridium difficile infection. N Engl J Med 2011;364:473-475.
41. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-289.
42. Jiang ZD, DuPont HL, LaRocco M, Garey KW. In vitro susceptibility of Clostridium difficile to rifaximin and ri-fampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol 2010;63:355-358.
43. Curry SR, Marsh JW, Shutt KA et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009;48:425-429.
44. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:547-552.
45. Boero M, Berti E, Morgando A, Verme G. Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs. vancomycin. Microbiologia Medica 1990;5:74-77.
46. Johnson S, Schriever C, Patel U et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with Rifaximin immediately post-vancomycin treatment. Anaerobe 2009;15:290-291.
47. Garey KW, Jiang ZD, Bellard A, Dupont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009;43:91-93.
48. Neff G, Zacharias V, Kaiser TE, et al. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series. Liver Transplantation 2010;16:960-963.
49. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-848.
50. Rubin DT, Sohi S, Glathar M, et al. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: Results of an open-label pilot study. Gastroenterol Res Pract 2011;2011:106978.
51. Mattila E, Arkkila P, Mattila PS, et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013;37:122-128.
52. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-427.
53. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: A randomized, double-blind study. Clin Infect Dis 2009;48:41-46.
54. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother 2011;45:1005-1010.
55. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205.
56. Kyne L. Clostridium difficile-Beyond antibiotics. N Engl J Med 2010;362:264-265.
57. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390-397.
58. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357: 189-193.
59. Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 1992;102:35-40.
60. Aldeyab MA, McElnay JC, Scott MG, et al. An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of Clostridium difficile infections. Infect Control Hosp Epidemiol 2011;32:631-633.
61. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 2007;35: 131-137.
62. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous im-munoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366-370.
63. Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991;118:633-637.
64. Wilcox MH. Descriptive study of intravenous immuno-globulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;53:882-884.
65. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-415.
66. Kelly CP. Fecal microbiota transplantation-An old therapy comes of age. N Engl J Med 2013;368:474-475.
67. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69:988-995.
68. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128:764-770.
69. Aboudola S, Kotloff KL, Kyne L et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect. Immun 2003;71:1608-1610.
70. Kotloff KL, Wasserman SS, Losonsky GA et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69:988-995.
71. Study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF™) in subjects with Clostridium difficile infection. http://clinicaltrials.gov/ct2/show/NCT00772343
72. Valneva. Clostridium difficile. www.valneva.com/?page = 85 (Last accessed April 14, 2014).
73. Rebeaud F, Bachmann MF. Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines 2012; 11:469-479.
74. Lee BY, Popovich MJ, Tian Y, et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010;28:5245-5253.
75. Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents 2009;33:4-7.
76. Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:2202-2204.
77. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011;(9):CD004610.
78. Musher DM, Aslam S. Treatment of Clostridium difficile colitis in the critical care setting. Crit Care Clin 2008;24:279-91.
79. Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis: Patterns of care and predictors of mortality. Arch Surg 2009;144:433-439.
80. Kim PK, Huh HC, Cohen HW, et al. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect 2013;14:532-539.
81. Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004;47:1620-1626.
82. Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2006;8:149-54.
83. Bhangu A, Nepogodiev D, Gupta A, et al; West Midlands Research Collaborative. Systematic review and metaanalysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012;99:1501-1513.
84. Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage. An alternative to total abdominal colectomy for the treatment of severe complicated Clostridium difficile-associated disease. Ann Surg 2011;254:423-429.
85. Oughton MT, et al. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp Epidemiol 2009; 30:939-944.